FDA Clearance Tracker · P210034-S001
Agili-C
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 4, 2026
Approved
Time to decision
175 days
Received Dec 11, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P210034-S001
- Device name
- Agili-C
- Applicant
- Smith and Nephew, Inc.
- Applicant location
- Andover, MA
- Received
- Dec 11, 2025
- Decided
- Jun 4, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P210034
Device type
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
Approval for updated package labeling that incorporates the clinical results from the required postapproval study.
Source documents
Other decisions for Smith and Nephew, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K222501 · Decided May 11, 2023 · 266 days after receipt
Device type: Mesh, Surgical, Collagen, Orthopaedics, Reinforcement Of Tendon (OWY) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.